Literature DB >> 25959748

Privileged scaffolds in lead generation.

Hongyu Zhao1, Justin Dietrich.   

Abstract

INTRODUCTION: The term "privileged scaffold" was coined in 1988 and the strategy was to construct high-affinity ligands from core structures that can bind more than one receptor. Since then, the privileged scaffold-based design has evolved from a stand-alone technology to an integral component of various lead generation platforms. AREAS COVERED: In this review, the authors discuss the applications of the privileged scaffold concept in current lead generation. Specifically, the authors cover the role that privileged scaffolds have played in the mass production of compounds to feed high-throughput screening (HTS) and its role in the design of ligands targeting protein-protein interactions, multiple ligands and warhead-based ligands. It is not the intention of the authors to review all privileged scaffolds known to date. Rather, the aim of this review is to highlight the strategic value of the concept of privileged scaffolds in various contemporary lead generation platforms. EXPERT OPINION: The privileged scaffolds as described by the original definition proved abundant in the available chemical space. HTS and other screening methods, in addition to greatly enhanced compound collections, make privileged scaffold-based design less relevant in finding high-affinity ligands than originally envisioned. However, the principle of privileged scaffolds has greatly enhanced and empowered current lead generation technologies.

Entities:  

Keywords:  binding warheads; high-throughput screening; multiple ligands; privileged scaffold; protein-protein interactions

Mesh:

Substances:

Year:  2015        PMID: 25959748     DOI: 10.1517/17460441.2015.1041496

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  12 in total

1.  Targeting mPGES-1 by a Combinatorial Approach: Identification of the Aminobenzothiazole Scaffold to Suppress PGE2 Levels.

Authors:  Maria G Chini; Assunta Giordano; Marianna Potenza; Stefania Terracciano; Katrin Fischer; Maria C Vaccaro; Ester Colarusso; Ines Bruno; Raffaele Riccio; Andreas Koeberle; Oliver Werz; Giuseppe Bifulco
Journal:  ACS Med Chem Lett       Date:  2020-03-05       Impact factor: 4.345

2.  N-Acylated and N-Alkylated 2-Aminobenzothiazoles Are Novel Agents That Suppress the Generation of Prostaglandin E2.

Authors:  Maria A Theodoropoulou; Anastasia Psarra; Martin Erhardt; Aikaterini Nikolaou; Anna-Dimitra D Gerogiannopoulou; Dimitra Hadjipavlou-Litina; Daiki Hayashi; Edward A Dennis; Andrea Huwiler; George Kokotos
Journal:  Biomolecules       Date:  2022-02-07

3.  Privileged Structures Revisited.

Authors:  Petra Schneider; Gisbert Schneider
Journal:  Angew Chem Int Ed Engl       Date:  2017-05-30       Impact factor: 15.336

4.  Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites.

Authors:  William Devine; Sarah M Thomas; Jessey Erath; Kelly A Bachovchin; Patricia J Lee; Susan E Leed; Ana Rodriguez; Richard J Sciotti; Kojo Mensa-Wilmot; Michael P Pollastri
Journal:  ACS Med Chem Lett       Date:  2017-02-05       Impact factor: 4.345

5.  High-speed vibration-milling-promoted synthesis of symmetrical frameworks containing two or three pyrrole units.

Authors:  Marco Leonardi; Mercedes Villacampa; J Carlos Menéndez
Journal:  Beilstein J Org Chem       Date:  2017-09-15       Impact factor: 2.883

Review 6.  Repurposing Estrogen Receptor Antagonists for the Treatment of Infectious Disease.

Authors:  Marhiah C Montoya; Damian J Krysan
Journal:  mBio       Date:  2018-12-18       Impact factor: 7.867

7.  Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform.

Authors:  Carolina B Moraes; Gesa Witt; Maria Kuzikov; Bernhard Ellinger; Theodora Calogeropoulou; Kyriakos C Prousis; Stefano Mangani; Flavio Di Pisa; Giacomo Landi; Lucia Dello Iacono; Cecilia Pozzi; Lucio H Freitas-Junior; Bruno Dos Santos Pascoalino; Claudia P Bertolacini; Birte Behrens; Oliver Keminer; Jennifer Leu; Markus Wolf; Jeanette Reinshagen; Anabela Cordeiro-da-Silva; Nuno Santarem; Alberto Venturelli; Stephen Wrigley; Deepa Karunakaran; Bethlehem Kebede; Ina Pöhner; Wolfgang Müller; Joanna Panecka-Hofman; Rebecca C Wade; Martina Fenske; Joachim Clos; José María Alunda; María Jesús Corral; Elisa Uliassi; Maria Laura Bolognesi; Pasquale Linciano; Antonio Quotadamo; Stefania Ferrari; Matteo Santucci; Chiara Borsari; Maria Paola Costi; Sheraz Gul
Journal:  SLAS Discov       Date:  2019-03       Impact factor: 3.341

8.  Artificial Intelligent Deep Learning Molecular Generative Modeling of Scaffold-Focused and Cannabinoid CB2 Target-Specific Small-Molecule Sublibraries.

Authors:  Yuemin Bian; Xiang-Qun Xie
Journal:  Cells       Date:  2022-03-07       Impact factor: 6.600

9.  Promising 2,6,9-Trisubstituted Purine Derivatives for Anticancer Compounds: Synthesis, 3D-QSAR, and Preliminary Biological Assays.

Authors:  Cristian O Salas; Ana Maria Zarate; Vladimir Kryštof; Jaime Mella; Mario Faundez; Jose Brea; María Isabel Loza; Ivan Brito; Denisa Hendrychová; Radek Jorda; Alan R Cabrera; Ricardo A Tapia; Christian Espinosa-Bustos
Journal:  Int J Mol Sci       Date:  2019-12-25       Impact factor: 5.923

10.  Pharmacoinformatic Investigation of Medicinal Plants from East Africa.

Authors:  Conrad V Simoben; Ammar Qaseem; Aurélien F A Moumbock; Kiran K Telukunta; Stefan Günther; Wolfgang Sippl; Fidele Ntie-Kang
Journal:  Mol Inform       Date:  2020-10-08       Impact factor: 3.353

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.